Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Conditions
Adult Fibrosarcoma - Alveolar Soft Part Sarcoma - Angiomatoid Fibrous Histiocytoma - Atypical Fibroxanthoma - Clear Cell Sarcoma of Soft Tissue - Epithelioid Malignant Peripheral Nerve Sheath Tumor - Epithelioid Sarcoma - Extraskeletal Myxoid Chondrosarcoma - Extraskeletal Osteosarcoma - Fibrohistiocytic Neoplasm - Glomus Tumor of the Skin - Inflammatory Myofibroblastic Tumor - Intimal Sarcoma - Leiomyosarcoma - Liposarcoma - Low Grade Fibromyxoid Sarcoma - Low Grade Myofibroblastic Sarcoma - Malignant Cutaneous Granular Cell Tumor - Malignant Peripheral Nerve Sheath Tumor - Malignant Triton Tumor - Mesenchymal Chondrosarcoma - Myxofibrosarcoma - Myxoid Chondrosarcoma - Myxoinflammatory Fibroblastic Sarcoma - Nerve Sheath Neoplasm - PEComa - Pericytic Neoplasm - Plexiform Fibrohistiocytic Tumor - Sclerosing Epithelioid Fibrosarcoma - Stage IB Soft Tissue Sarcoma - Stage IIB Soft Tissue Sarcoma - Stage III Soft Tissue Sarcoma - Stage IV Soft Tissue Sarcoma - Synovial Sarcoma - Undifferentiated (Embryonal) Sarcoma - Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Conditions: official terms
Chondrosarcoma - Chondrosarcoma, Mesenchymal - Fibrosarcoma - Glomus Tumor - Granular Cell Tumor - Granuloma, Plasma Cell - Histiocytoma - Histiocytoma, Benign Fibrous - Histiocytoma, Malignant Fibrous - Leiomyosarcoma - Liposarcoma - Neoplasms - Nerve Sheath Neoplasms - Neurilemmoma - Neurofibroma - Neurofibrosarcoma - Osteosarcoma - Sarcoma - Sarcoma, Alveolar Soft Part - Sarcoma, Clear Cell - Sarcoma, Synovial - Skin Neoplasms
Study Type
Interventional
Study Phase
Phase 2/Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Doxorubicin Hydrochloride Type: Drug
Name: Ifosfamide Type: Drug
Name: Laboratory Biomarker Analysis Type: Other
Name: Pazopanib Hydrochloride Type: Drug
Name: Pharmacological Study Type: Other
Name: Radiation Therapy Type: Radiation
Name: Therapeutic Conventional Surgery Type: Procedure
Overall Status
Recruiting
Summary
This randomized phase II/III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Detailed Description
PRIMARY OBJECTIVES:

I. To identify the dose of pazopanib (pazopanib hydrochloride) that is feasible when given in combination with radiation or chemoradiation in pediatric and adult patients newly diagnosed with unresected intermediate- and high-risk non-rhabdomyosarcoma soft tissue sarcomas (NRSTS).

II. To compare the rates of near complete pathologic response (> 90% necrosis) with the addition of pazopanib to preoperative chemoradiation versus preoperative chemoradiation alone for potentially resectable > 5 cm, grade 3 intermediate to high risk chemotherapy-sensitive NRSTS in the phase II portion of the study for this cohort.

III. To compare the rates of near complete pathologic response (> 90% necrosis) with the addition of pazopanib to preoperative radiotherapy versus preoperative radiotherapy alone for potentially resectable intermediate to high risk adult and pediatric NRSTS in the phase II portion of the study for this cohort (using a phase II decision rule to go onto the phase III portion of the study).

IV. To compare the rates of event-free survival (EFS) with the addition of pazopanib to preoperative radiotherapy versus preoperative radiotherapy alone for localized intermediate to high risk adult and pediatric NRSTS in the phase III portion of the study for this cohort if the phase II decision rule is passed.

SECONDARY OBJECTIVES:

I. To estimate the rates of local failure, regional failure, distant metastasis free survival, disease-free survival, and overall survival with the addition of pazopanib to preoperative chemoradiation or preoperative radiation in intermediate to high risk adult and pediatric NRSTS.

II. To compare the pattern of recurrence (local, regional and distant) between preoperative chemoradiation or radiation with the addition of pazopanib for adult and pediatric NRSTS.

III. To define the toxicities of ifosfamide and doxorubicin (doxorubicin hydrochloride) chemotherapy and radiation when used in combination with pazopanib in intermediate to high risk adult and pediatric NRSTS.

IV. To define the toxicities of preoperative radiotherapy when used in combination with pazopanib in intermediate to high risk adult and pediatric NRSTS.

TERTIARY OBJECTIVES:

I. To gain insight into the disease biology of childhood and adult NRSTS through analysis of actionable mutations and whole genome sequencing.

II. To determine if microvessel density and circulating tumor deoxyribonucleic acid (DNA) predict response to pazopanib and outcome.

III. To determine the effect of pazopanib on doxorubicin exposure in children and adults with NRSTS.

IV. To evaluate change in fludeoxyglucose F 18 (FDG) positron emission tomography (PET) maximum standard uptake value (SUVmax) from baseline to week 10 or 13 in patients with unresected tumors and to correlate this change with pathologic response and EFS.

V. To compare the rate of response by standard imaging and pathologic assessment to determine which correlates better with local tumor control, distant tumor control, EFS, and overall survival.

OUTLINE: This is a dose-escalation study of pazopanib hydrochloride.

CHEMOTHERAPY COHORT: Patients eligible for chemotherapy cohort are randomized to 1 of 2 treatment regimens.

REGIMEN A:

INDUCTION PHASE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on weeks 1-12, ifosfamide intravenously (IV) over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10, and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4. Patients undergo radiation therapy on weeks 4-10.

SURGERY: Patients undergo surgery on week 13.

CONTINUATION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 16-25, ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19, and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22. Patients undergo radiation therapy on weeks 16-25 for a total of 45 Gy.

REGIMEN B:

INDUCTION PHASE: Patients receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4. Patients undergo radiation therapy on weeks 4-10.

SURGERY: Patients undergo surgery on week 13.

CONTINUATION PHASE: Patients receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22. Patients undergo radiation therapy on weeks 16-25 for a total of 45 Gy.

NON-CHEMOTHERAPY COHORT: Patients eligible for non-chemotherapy cohort are randomized to 1 of 2 treatment regimens.

REGIMEN C:

INDUCTION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.

SURGERY: Patients undergo surgery on week 10.

CONTINUATION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 13-25. Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy.

REGIMEN D:

INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.

SURGERY: Patients undergo surgery on week 10.

CONTINUATION PHASE: Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy.

After completion of study treatment, patients are followed up at 6, 12, 18, 24, 30, 36, 48, and 60 months.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 2 Years
Gender: Both
Criteria: Inclusion Criteria:

- Newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk will be eligible for the chemotherapy or non-chemotherapy cohort based on:

- Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials

- Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade and

- Medically deemed able or unable to undergo chemotherapy

- Notes: an incisional biopsy or core biopsy is preferred; fine needle aspiration biopsy is not acceptable to establish the diagnosis

- ELIGIBLE SITES:

- Extremities: upper (including shoulder) and lower (including hip)

- Trunk: body wall

- INELIGIBLE SITES: Head and neck, visceral organs (with the exception of embryonal sarcoma of the liver), retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis

- ELIGIBILITY FOR CHEMOTHERAPY COHORT:

- Stage T2a/b (> 5 cm) and grade 3 AND

- One of the following chemosensitive histologies as defined in the World Health Organization (WHO) classification of soft tissue tumors (with some evidence of good response to chemoradiation and of sufficient high risk of metastases, or clear evidence of metastases):

- Unclassified soft tissue sarcomas that are too undifferentiated to be placed in a specific pathologic category in the WHO classification (often called "undifferentiated soft tissue sarcoma" or "soft tissue sarcoma not otherwise specified [NOS]")

- Synovial sarcoma

- Angiosarcoma of soft tissue

- Adult fibrosarcoma

- Mesenchymal (extraskeletal) chondrosarcoma

- Leiomyosarcoma

- Liposarcoma (excluding myxoid liposarcoma)

- Undifferentiated pleomorphic sarcoma

- Embryonal sarcoma of the liver

- Patients meeting the above criteria (histology, size, and grade) with the EXCEPTION of histologies noted above may enroll on the chemotherapy cohort or the non-chemotherapy cohort at the discretion of the enrolling investigator; patients meeting these criteria with the EXCEPTION of histologies noted above but medically deemed unable to receive chemotherapy or who elect not to receive chemotherapy are eligible for the non-chemotherapy cohort

- Patients with the following histologies are only eligible for the chemotherapy cohort and cannot enroll on the non-chemotherapy cohort:

- Unclassified soft tissue sarcomas that are too undifferentiated to be placed in a specific pathologic category in the WHO classification (often called "undifferentiated soft tissue sarcoma" or "soft tissue sarcoma NOS") in patients < 30 years of age

- Synovial sarcoma

- Embryonal sarcoma of the liver

- ELIGIBILITY FOR NON-CHEMOTHERAPY COHORT:

- Patients with any size of grade 2 or 3 of the following "intermediate (rarely metastasizing)" or "malignant" tumors, as defined in the WHO classification of soft tissue tumors for which we have consensus data of chemotherapy-resistance are eligible only for the non-chemotherapy cohort:

- So-called fibrohistiocytic tumors - plexiform fibrohistiocytic tumor, giant cell tumor of soft tissues

- Fibroblastic/myofibroblastic tumors - solitary fibrous tumor, malignant solitary fibrous tumor, inflammatory myofibroblastic tumor, low grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma, atypical myxoinflammatory fibroblastic tumor, myxofibrosarcoma, low grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma

- Tumors of uncertain differentiation - epithelioid sarcoma, alveolar soft part sarcoma, clear cell sarcoma of soft tissue, angiomatoid fibrous histiocytoma, ossifying fibromyxoid tumor, myoepithelioma, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, neoplasms with perivascular epithelioid cell differentiation (PEComa), intimal sarcoma, atypical fibroxanthoma, mixed tumor NOS, phosphaturic mesenchymal tumor, malignant ossifying fibromyxoid tumor, malignant mixed tumor, malignant phosphaturic mesenchymal tumor

- Chondro-osseous tumors - extraskeletal osteosarcoma

- Pericytic (perivascular) tumors - malignant glomus tumor

- Nerve sheath tumors - malignant peripheral nerve sheath tumor, malignant granular cell tumor, epithelioid malignant peripheral nerve sheath tumor, malignant Triton tumor

- Undifferentiated sarcomas (with a specific pathologic category in the WHO classification) - undifferentiated round cell sarcoma, undifferentiated epithelioid sarcoma, undifferentiated spindle cell sarcoma

- Patients meeting the criteria (histology, size, and grade) with the EXCEPTION of histologies noted above may enroll on the non-chemotherapy cohort at the discretion of the enrolling investigator; patients meeting these criteria with the EXCEPTION of histologies noted above but medically deemed unable to receive chemotherapy or who elect not to receive chemotherapy are eligible for the non-chemotherapy cohort; Note that tumors arising in bone are NOT eligible for this study

- Extent of disease:

- Patients with non-metastatic and metastatic disease are eligible

- Initially unresectable patients, with or without metastatic disease, are eligible as long as there is a commitment at enrollment to resect the primary tumor

- Sufficient tissue and blood must be available to submit for required biology studies

- Lansky performance status score >= 70 for patients =< 16 years of age

- Karnofsky performance status score >= 70 for patients > 16 years of age

- Absolute neutrophil count >= 1500/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility

- Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility

- Hemoglobin >= 8 g/dL for patients =< 16 years of age; >= 9 g/dL for patients > 16 years of age; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or normal serum creatinine based on age/gender as follows:

- 2 to < 6 years; 0.8 mg/dL male; 0.8 mg/dL female

- 6 to < 10 years; 1 mg/dL male; 1 mg/dL female

- 10 to < 13 years; 1.2 mg/dL male; 1.2 mg/dL female

- 13 to < 16 years; 1.5 mg/dL male; 1.4 mg/dL female

- >= 16 years; 1.5 mg/dL male; 1.4 mg/dL female

- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]) or serum glutamate pyruvate transaminase [SGPT] (alanine transaminase [ALT]) < 2.5 x upper limit of normal (ULN) for age

- Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogram

- Corrected QT interval (QTc) < 480 msec

- No evidence of dyspnea at rest, no exercise intolerance, and a resting pulse oximetry reading > 94% on room air if there is clinical indication for determination

- Patients on low molecular weight heparin or Coumadin (with a stable international normalized ratio [INR]) are eligible

- Patient must have a life expectancy of at least 3 months with appropriate therapy

- All patients and/or their parents or legal guardians must sign a written informed consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Exclusion Criteria:

- Patients with grade 1 NRSTS tumors of any size are not eligible

- Patients with known central nervous system (CNS) metastases are not eligible; Note: brain imaging is not an eligibility requirement

- Patients with evidence of active bleeding or bleeding diathesis will be excluded (Note: patients aged > 17 years with excess of 2.5 mL of hemoptysis are not eligible)

- Patients with gross total resection of the primary tumor prior to enrollment on ARST1321 are NOT eligible; patients who have experienced tumor recurrence after a gross total tumor resection are NOT eligible

- Patients with uncontrolled hypertension are ineligible; uncontrolled hypertension is defined as follows:

- Patients aged =< 17 years: greater than 95th percentile systolic and diastolic blood pressure based on age and height which is not controlled by one anti-hypertensive medication

- Patients aged > 17 years: systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg that is not controlled by one anti-hypertensive medication

- Prior Therapy:

- Patients must have had no prior anthracycline (eg, doxorubicin, daunorubicin) or ifosfamide chemotherapy

- Patients must have had no prior use of pazopanib or similar multi-targeted tyrosine kinase inhibitors (TKI)

- Patients must have had no prior radiotherapy to tumor-involved sites

- Note: patients previously treated for a non-NRSTS cancer are eligible provided they meet the prior therapy requirements; patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded

- Other types of invasive malignancy that are not disease free within 3 years except for non-melanoma skin cancer, lentigo maligna, any carcinoma-in-situ or prostate cancer with low risk factors

- CYTOCHROME P450 3A4 (CYP3A4) substrates WITH narrow therapeutic indices: patients chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices within 7 days prior to study enrollment, including but not limited to pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; Note: the use of fentanyl is permitted

- CYP3A4 Inhibitors: patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment, including but not limited to itraconazole, clarithromycin, erythromycin many non-nucleoside reverse-transcriptase inhibitors (NNRTIs), diltiazem, verapamil, and grapefruit juice are not eligible

- CYP3A4 Inducers: patients chronically receiving drugs that are known potent CYP3A4 inducers within 14 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's wort are not eligible (with the exception of glucocorticoids)

- Certain medications that are associated with a risk for QTc prolongation and/or Torsades de Pointes, although not prohibited, should be avoided or replaced with medications that do not carry these risks, if possible

- Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:

- Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills

- Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel

- Active peptic ulcer disease

- Malabsorption syndrome

- Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:

- Active peptic ulcer disease

- Known intraluminal metastatic lesions

- Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions which increase the risk of perforation

- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to beginning study treatment

- Subjects with any of the following cardiovascular conditions within the past 6 months

- Cerebrovascular accident (CVA) or transient ischemic attack (TIA)

- Cardiac arrhythmia

- Admission for unstable angina

- Cardiac angioplasty or stenting

- Coronary artery bypass graft surgery

- Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation for less than 6 weeks

- Arterial thrombosis

- Symptomatic peripheral vascular disease

- Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; a subject who has a history of class II heart failure and is asymptomatic on treatment may be considered eligible

- History of serious or non-healing wound, ulcer, or bone fracture

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Patients who are unable to swallow whole tablets are not eligible

- Patients with a body surface area < 0.5 m^2 are not be eligible

- Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

- Patients who are receiving any other investigational agent(s)

- Pregnancy and breast feeding:

- Female patients who are pregnant are ineligible

- Lactating females are not eligible unless they have agreed not to breastfeed their infants during treatment and for a period of 1 month following completion of treatment

- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained

- Unwillingness to use an effective contraceptive method for the duration of their study participation and for at least 1 month after treatment is completed if sexually active with reproductive potential
Locations
Children's Hospital of Alabama
Birmingham, Alabama, United States
Status: Recruiting
Contact: Alyssa T. Reddy - 888-823-5923 - ctsucontact@westat.com
Phoenix Childrens Hospital
Phoenix, Arizona, United States
Status: Recruiting
Contact: Jessica Boklan - 602-546-0920
The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States
Status: Recruiting
Contact: Lisa M. Kopp - 520-626-9008
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Status: Recruiting
Contact: David L. Becton - 501-364-7373
Southern California Permanente Medical Group
Downey, California, United States
Status: Recruiting
Contact: Robert M. Cooper - 626-564-3455
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Status: Recruiting
Contact: Anna B. Pawlowska - 800-826-4673 - becomingapatient@coh.org
Loma Linda University Medical Center
Loma Linda, California, United States
Status: Recruiting
Contact: Albert Kheradpour - 909-558-3375
Miller Children's and Women's Hospital Long Beach
Long Beach, California, United States
Status: Recruiting
Contact: Cecilia H. Fu - 323-361-4110
Children's Hospital Los Angeles
Los Angeles, California, United States
Status: Recruiting
Contact: Leo Mascarenhas - 323-361-4110
Children's Hospital Central California
Madera, California, United States
Status: Recruiting
Contact: Vonda L. Crouse - 866-353-5437
Children's Hospital and Research Center at Oakland
Oakland, California, United States
Status: Recruiting
Contact: Carla B. Golden - 510-450-7600
Kaiser Permanente-Oakland
Oakland, California, United States
Status: Recruiting
Contact: Samantha A. Seaward - 626-564-3455
Childrens Hospital of Orange County
Orange, California, United States
Status: Recruiting
Contact: Violet Shen - 714-997-3000
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, United States
Status: Recruiting
Contact: Neyssa M. Marina - 650-498-7061 - clinicaltrials@med.stanford.edu
Sutter General Hospital
Sacramento, California, United States
Status: Recruiting
Contact: Yung S. Yim - 415-209-2686 - bernicl@sutterhealth.org
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Status: Recruiting
Contact: Arta M. Monjazeb - 916-734-3089
Rady Children's Hospital - San Diego
San Diego, California, United States
Status: Recruiting
Contact: William D. Roberts - 858-966-5934
UCSF Medical Center-Mission Bay
San Francisco, California, United States
Status: Recruiting
Contact: Robert E. Goldsby - 877-827-3222
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States
Status: Recruiting
Contact: Joseph L. Lasky - 888-662-8252
Children's Hospital Colorado
Aurora, Colorado, United States
Status: Recruiting
Contact: Timothy P. Garrington - 720-777-6672
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado, United States
Status: Recruiting
Contact: Jennifer J. Clark - 866-775-6246
Connecticut Children's Medical Center
Hartford, Connecticut, United States
Status: Recruiting
Contact: Michael S. Isakoff - 860-545-9981
Yale University
New Haven, Connecticut, United States
Status: Recruiting
Contact: Nina S. Kadan-Lottick - 203-785-5702
Alfred I duPont Hospital for Children
Wilmington, Delaware, United States
Status: Recruiting
Contact: Scott M. Bradfield - 904-697-3529
Children's National Medical Center
Washington, District of Columbia, United States
Status: Recruiting
Contact: Jeffrey S. Dome - 202-884-2549
MedStar Georgetown University Hospital
Washington, District of Columbia, United States
Status: Recruiting
Contact: Aziza T. Shad - 202-444-0381
University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Status: Recruiting
Contact: Breelyn A. Wilky - 866-574-5124 - Sylvester@emergingmed.com
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida, United States
Status: Recruiting
Contact: Emad K. Salman - 239-343-5333
University of Florida
Gainesville, Florida, United States
Status: Recruiting
Contact: William B. Slayton - 352-273-8675 - trials@cancer.ufl.edu
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, United States
Status: Recruiting
Contact: Iftikhar Hanif - 954-265-2234
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida, United States
Status: Recruiting
Contact: Scott M. Bradfield - 904-697-3529
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Status: Recruiting
Contact: Julio C. Barredo - 866-574-5124 - Sylvester@emergingmed.com
Florida Hospital Orlando
Orlando, Florida, United States
Status: Recruiting
Contact: Fouad M. Hajjar - 407-303-5623
Nemours Children's Hospital
Orlando, Florida, United States
Status: Recruiting
Contact: Scott M. Bradfield - 904-697-3529
Nemours Children's Clinic - Pensacola
Pensacola, Florida, United States
Status: Recruiting
Contact: Scott M. Bradfield - 904-697-3529
All Children's Hospital
Saint Petersburg, Florida, United States
Status: Recruiting
Contact: Gregory A. Hale - 727-767-2423 - HamblinF@allkids.org
Saint Joseph's Hospital/Children's Hospital-Tampa
Tampa, Florida, United States
Status: Recruiting
Contact: Dana A. Obzut - 800-882-4123
Saint Mary's Hospital
West Palm Beach, Florida, United States
Status: Recruiting
Contact: Narayana Gowda - 888-823-5923 - ctsucontact@westat.com
Children's Healthcare of Atlanta - Egleston
Atlanta, Georgia, United States
Status: Recruiting
Contact: Thomas A. Olson - 404-785-1112
Georgia Regents University Medical Center
Augusta, Georgia, United States
Status: Recruiting
Contact: Colleen H. McDonough - 706-721-1663 - cancer@georgiahealth.edu
Memorial University Medical Center
Savannah, Georgia, United States
Status: Recruiting
Contact: J. M. Johnston - 912-350-8568
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, United States
Status: Recruiting
Contact: Eugenia Chang - 800-845-4624
Lurie Children's Hospital-Chicago
Chicago, Illinois, United States
Status: Recruiting
Contact: David O. Walterhouse - 773-880-4562
Northwestern University
Chicago, Illinois, United States
Status: Recruiting
Contact: Mark Agulnik - 312-695-1301 - cancer@northwestern.edu
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Status: Recruiting
Contact: Navin R. Pinto - 773-834-7424
University of Illinois
Chicago, Illinois, United States
Status: Recruiting
Contact: Mary L. Schmidt - 312-355-3046
Loyola University Medical Center
Maywood, Illinois, United States
Status: Recruiting
Contact: Eugene Suh - 708-226-4357
UC Comprehensive Cancer Center at Silver Cross
New Lennox, Illinois, United States
Status: Recruiting
Contact: Navin R. Pinto - 773-834-7424
Advocate Children's Hospital-Oak Lawn
Oak Lawn, Illinois, United States
Status: Recruiting
Contact: Rebecca E. McFall - 847-723-7570
Advocate Children's Hospital-Park Ridge
Park Ridge, Illinois, United States
Status: Recruiting
Contact: Jong-Hyo Kwon - 847-384-3621
Saint Jude Midwest Affiliate
Peoria, Illinois, United States
Status: Recruiting
Contact: Karen S. Fernandez - 309-655-3258
Memorial Medical Center
Springfield, Illinois, United States
Status: Recruiting
Contact: Gregory P. Brandt - 217-545-7929
Saint John's Hospital
Springfield, Illinois, United States
Status: Recruiting
Contact: Gregory P. Brandt - 217-545-7929
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Status: Recruiting
Contact: Gregory P. Brandt - 217-545-7929
Riley Hospital for Children
Indianapolis, Indiana, United States
Status: Recruiting
Contact: Robert J. Fallon - 888-823-5923 - ctsucontact@westat.com
Saint Vincent Hospital and Health Services
Indianapolis, Indiana, United States
Status: Recruiting
Contact: Bassem I. Razzouk - 317-338-2194
Reid Hospital and Health Care Services
Richmond, Indiana, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Blank Children's Hospital
Des Moines, Iowa, United States
Status: Recruiting
Contact: Wendy L. Woods-Swafford - 515-241-6729
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
Status: Recruiting
Contact: Ayman A. El-Sheikh - 800-237-1225
Siouxland Regional Cancer Center
Sioux City, Iowa, United States
Status: Recruiting
Contact: Donald B. Wender - 712-252-0088
Newman Regional Health
Emporia, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Saint Catherine Hospital
Garden City, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Saint Rose Ambulatory and Surgery Center
Great Bend, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Hays Medical Center
Hays, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
University of Kansas Cancer Center
Kansas City, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Olathe Medical Center
Olathe, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Kansas City Cancer Centers-Southwest
Overland Park, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Via Christi Hospital-Pittsburg
Pittsburg, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Salina Regional Health Center
Salina, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Saint Francis Hospital and Medical Center - Topeka
Topeka, Kansas, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, United States
Status: Recruiting
Contact: Lars M. Wagner - 859-257-3379
Kosair Children's Hospital
Louisville, Kentucky, United States
Status: Recruiting
Contact: Kenneth G. Lucas - 866-530-5516
Children's Hospital New Orleans
New Orleans, Louisiana, United States
Status: Recruiting
Contact: Lolie C. Yu - 504-894-5377
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States
Status: Recruiting
Contact: Craig Lotterman - 888-562-4763
Eastern Maine Medical Center
Bangor, Maine, United States
Status: Recruiting
Contact: Sam W. Lew - 207-973-4274
Maine Children's Cancer Program
Scarborough, Maine, United States
Status: Recruiting
Contact: Aaron R. Weiss - 207-396-8090 - wrighd@mmc.org
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Status: Recruiting
Contact: David M. Loeb - 410-955-8804 - jhcccro@jhmi.edu
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Status: Recruiting
Contact: Joseph M. Wiley - 410-601-6120 - pridgely@lifebridgehealth.org
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
Status: Recruiting
Contact: Anne B. Warwick - 301-319-2100
University of Massachusetts Medical School
Worcester, Massachusetts, United States
Status: Recruiting
Contact: Christopher P. Keuker - 508-856-3216 - cancer.research@umassmed.edu
C S Mott Children's Hospital
Ann Arbor, Michigan, United States
Status: Recruiting
Contact: Rajen Mody - 800-865-1125
Henry Ford Hospital
Detroit, Michigan, United States
Status: Recruiting
Contact: Robert A. Chapman - 313-916-1784
Saint John Hospital and Medical Center
Detroit, Michigan, United States
Status: Recruiting
Contact: Hadi Sawaf - 313-343-3166
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Status: Recruiting
Contact: Zhihong J. Wang - 313-576-9363
Hurley Medical Center
Flint, Michigan, United States
Status: Recruiting
Contact: Susumu Inoue - 888-606-6556
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Mercy Health Saint Mary's
Grand Rapids, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Borgess Medical Center
Kalamazoo, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Bronson Methodist Hospital
Kalamazoo, Michigan, United States
Status: Recruiting
Contact: Katharina E. Elliott - 800-227-2345
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Mercy Health Mercy Campus
Muskegon, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Spectrum Health Reed City Hospital
Reed City, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Beaumont Children's Hospital-Royal Oak
Royal Oak, Michigan, United States
Status: Recruiting
Contact: Laura K. Gowans - 248-551-7695
Lakeland Hospital
St. Joseph, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Munson Medical Center
Traverse City, Michigan, United States
Status: Recruiting
Contact: Gilbert D. Padula - 616-685-5225 - connie.szczepanek@grcop.org
Essentia Health Cancer Center
Duluth, Minnesota, United States
Status: Recruiting
Contact: Emily G. Greengard - 612-624-2620
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota, United States
Status: Recruiting
Contact: Michael K. Richards - 612-813-5193
University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota, United States
Status: Recruiting
Contact: Emily G. Greengard - 612-624-2620
Mayo Clinic
Rochester, Minnesota, United States
Status: Recruiting
Contact: Carola A. Arndt - 507-538-7623
University of Mississippi Medical Center
Jackson, Mississippi, United States
Status: Recruiting
Contact: Gail C. Megason - 601-815-6700
Columbia Regional
Columbia, Missouri, United States
Status: Recruiting
Contact: Thomas W. Loew - 573-882-7440
Freeman Health System
Joplin, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Kansas City Cancer Center - South
Kansas City, Missouri, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Kansas City Cancer Centers - North
Kansas City, Missouri, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
The Childrens Mercy Hospital
Kansas City, Missouri, United States
Status: Recruiting
Contact: Maxine L. Hetherington - 816-234-3265
Kansas City Cancer Center-Lee's Summit
Lee's Summit, Missouri, United States
Status: Recruiting
Contact: Joshua M. Mammen - 913-945-7552 - ctnursenav@kumc.edu
Phelps County Regional Medical Center
Rolla, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Saint John's Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Cardinal Glennon Children's Medical Center
Saint Louis, Missouri, United States
Status: Recruiting
Contact: William S. Ferguson - 314-268-4000
Mercy Hospital Saint Louis
Saint Louis, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Washington University School of Medicine
Saint Louis, Missouri, United States
Status: Recruiting
Contact: Frederick S. Huang - 800-600-3606 - info@siteman.wustl.edu
CoxHealth South Hospital
Springfield, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Mercy Hospital Springfield
Springfield, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Children's Hospital and Medical Center of Omaha
Omaha, Nebraska, United States
Status: Recruiting
Contact: Minnie Abromowitch - 402-955-3949
University of Nebraska Medical Center
Omaha, Nebraska, United States
Status: Recruiting
Contact: Minnie Abromowitch - 402-955-3949
21st Century Oncology
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Jonathan Bernstein - 702-384-0013
Children's Specialty Center of Nevada II
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Jonathan Bernstein - 702-384-0013
Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Jonathan Bernstein - 702-384-0013
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Jonathan Bernstein - 702-384-0013
Summerlin Hospital Medical Center
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Jonathan Bernstein - 702-384-0013
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Status: Recruiting
Contact: Sara Chaffee - 800-639-6918 - cancer.research.nurse@dartmouth.edu
Hackensack University Medical Center
Hackensack, New Jersey, United States
Status: Recruiting
Contact: Burton E. Appel - 201-996-2879
Morristown Medical Center
Morristown, New Jersey, United States
Status: Recruiting
Contact: Steven L. Halpern - 973-971-5900
Saint Peter's University Hospital
New Brunswick, New Jersey, United States
Status: Recruiting
Contact: Stanley Calderwood - 732-745-8600 - kcovert@saintpetersuh.com
UMDNJ - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
Status: Recruiting
Contact: Richard A. Drachtman - 732-235-8675
Newark Beth Israel Medical Center
Newark, New Jersey, United States
Status: Recruiting
Contact: Peri Kamalakar - 973-926-7230
Saint Joseph's Regional Medical Center
Paterson, New Jersey, United States
Status: Recruiting
Contact: Mary A. Bonilla - 973-754-2909
University of New Mexico
Albuquerque, New Mexico, United States
Status: Recruiting
Contact: Koh B. Boayue - 505-272-6972
Albany Medical Center
Albany, New York, United States
Status: Recruiting
Contact: Vikramjit S. Kanwar - 518-262-3368
Montefiore Medical Center - Moses Campus
Bronx, New York, United States
Status: Recruiting
Contact: Peter D. Cole - 718-904-2730 - aecc@aecom.yu.edu
Roswell Park Cancer Institute
Buffalo, New York, United States
Status: Recruiting
Contact: Nikhil I. Khushalani - 877-275-7724
Winthrop University Hospital
Mineola, New York, United States
Status: Recruiting
Contact: Mark E. Weinblatt - 866-946-8476
The Steven and Alexandra Cohen Children's Medical Center of New York
New Hyde Park, New York, United States
Status: Recruiting
Contact: Carolyn F. Levy - 718-470-3470
Columbia University Medical Center
New York, New York, United States
Status: Recruiting
Contact: Alice Lee - 212-305-8615
Laura and Issac Perlmutter Cancer Center at NYU Langone
New York, New York, United States
Status: Recruiting
Contact: Sharon L. Gardner - 212-263-4434 - prmc.coordinator@nyumc.org
University of Rochester
Rochester, New York, United States
Status: Recruiting
Contact: Jeffrey R. Andolina - 585-275-5830
State University of New York Upstate Medical University
Syracuse, New York, United States
Status: Recruiting
Contact: Karol H. Kerr - 315-464-5476
New York Medical College
Valhalla, New York, United States
Status: Recruiting
Contact: Jessica C. Hochberg - 914-594-3794
Mission Hospital-Memorial Campus
Asheville, North Carolina, United States
Status: Recruiting
Contact: Douglas J. Scothorn - 828-213-4150
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Status: Recruiting
Contact: Stuart H. Gold - 877-668-0683 - cancerclinicaltrials@med.unc.edu
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, United States
Status: Recruiting
Contact: Joel A. Kaplan - 704-355-2884
Duke University Medical Center
Durham, North Carolina, United States
Status: Recruiting
Contact: Susan G. Kreissman - 888-275-3853
East Carolina University
Greenville, North Carolina, United States
Status: Recruiting
Contact: George E. Hucks - 252-744-2391
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Status: Recruiting
Contact: Sharon M. Castellino - 336-713-6771
Sanford Medical Center-Fargo
Fargo, North Dakota, United States
Status: Recruiting
Contact: Samuel O. Anim - 701-234-6161
Children's Hospital Medical Center of Akron
Akron, Ohio, United States
Status: Recruiting
Contact: Steven J. Kuerbitz - 330-543-3193
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Status: Recruiting
Contact: John P. Perentesis - 513-636-2799
Oncology Hematology Care Inc-Blue Ash
Cincinnati, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Status: Recruiting
Contact: Margaret C. Thompson - 866-223-8100
Rainbow Babies and Childrens Hospital
Cleveland, Ohio, United States
Status: Recruiting
Contact: Yousif (Joe) H. Matloub - 216-844-5437
Nationwide Children's Hospital
Columbus, Ohio, United States
Status: Recruiting
Contact: Mark A. Ranalli - 614-722-2708
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Status: Recruiting
Contact: Meng X. Welliver - 800-293-5066 - Jamesline@osumc.edu
Dayton Children's Hospital
Dayton, Ohio, United States
Status: Recruiting
Contact: Ayman A. El-Sheikh - 800-237-1225
Good Samaritan Hospital - Dayton
Dayton, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Miami Valley Hospital
Dayton, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Samaritan North Health Center
Dayton, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Blanchard Valley Hospital
Findlay, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Wayne Hospital
Greenville, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Kettering Medical Center
Kettering, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Springfield Regional Medical Center
Springfield, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
The Toledo Hospital/Toledo Children's Hospital
Toledo, Ohio, United States
Status: Recruiting
Contact: Jamie L. Dargart - 419-824-1842
Upper Valley Medical Center
Troy, Ohio, United States
Status: Recruiting
Contact: Howard M. Gross - 937-775-1350
Wright-Patterson Medical Center
Wright-Patterson Afb, Ohio, United States
Status: Active, not recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Status: Recruiting
Contact: Robert S. Mannel - 405-271-4272 - julie-traylor@ouhsc.edu
Legacy Emanuel Children's Hospital
Portland, Oregon, United States
Status: Recruiting
Contact: Janice F. Olson - 503-413-2560
Oregon Health and Science University
Portland, Oregon, United States
Status: Recruiting
Contact: Suman Malempati - 503-494-1080 - trials@ohsu.edu
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, United States
Status: Recruiting
Contact: Philip M. Monteleone - 484-884-2201
Penn State Hershey Children's Hospital
Hershey, Pennsylvania, United States
Status: Recruiting
Contact: Lisa M. McGregor - 717-531-6012
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Richard B. Womer - 215-590-2810
Drexel University School of Medicine
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Akash Nahar - 215-427-8991
Saint Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Akash Nahar - 215-427-8991
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Status: Recruiting
Contact: Jean M. Tersak - 412-692-5573
Lankenau Medical Center
Wynnewood, Pennsylvania, United States
Status: Recruiting
Contact: Albert S. DeNittis - 866-225-5654
Rhode Island Hospital
Providence, Rhode Island, United States
Status: Recruiting
Contact: Jennifer J. Greene Welch - 401-444-1488
Medical University of South Carolina
Charleston, South Carolina, United States
Status: Recruiting
Contact: Jacqueline M. Kraveka - 843-792-9321
Palmetto Health Richland
Columbia, South Carolina, United States
Status: Recruiting
Contact: Ronnie W. Neuberg - 803-434-3680
BI-LO Charities Children's Cancer Center
Greenville, South Carolina, United States
Status: Recruiting
Contact: Nichole L. Bryant - 864-241-6251
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Memorial Hospital
Greenville, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, United States
Status: Recruiting
Contact: David L. Grisell - 864-241-6251
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, United States
Status: Recruiting
Contact: Kayelyn J. Wagner - 605-328-1367
T C Thompson Children's Hospital
Chattanooga, Tennessee, United States
Status: Recruiting
Contact: Manoo G. Bhakta - 423-778-7289
East Tennessee Childrens Hospital
Knoxville, Tennessee, United States
Status: Recruiting
Contact: Ray C. Pais - 865-541-8266
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
Status: Recruiting
Contact: Wayne L. Furman - 866-278-5833 - info@stjude.org
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
Status: Recruiting
Contact: Scott C. Borinstein - 800-811-8480
Dell Children's Medical Center of Central Texas
Austin, Texas, United States
Status: Recruiting
Contact: Amy C. Fowler - 214-648-7097
Driscoll Children's Hospital
Corpus Christi, Texas, United States
Status: Recruiting
Contact: M. C. Johnson - 361-694-5311
Medical City Dallas Hospital
Dallas, Texas, United States
Status: Recruiting
Contact: Stanton C. Goldman - 972-566-5588
Parkland Memorial Hospital
Dallas, Texas, United States
Status: Recruiting
Contact: Andrew A. Martin - 214-648-7097
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States
Status: Recruiting
Contact: Andrew A. Martin - 214-648-7097
El Paso Children's Hospital
El Paso, Texas, United States
Status: Recruiting
Contact: Lisa L. Hartman - 888-823-5923 - ctsucontact@westat.com
Cook Children's Medical Center
Fort Worth, Texas, United States
Status: Recruiting
Contact: Karen H. Albritton - 682-885-2103
Baylor College of Medicine
Houston, Texas, United States
Status: Recruiting
Contact: Mehmet F. Okcu - 713-798-1354 - burton@bcm.edu
M D Anderson Cancer Center
Houston, Texas, United States
Status: Recruiting
Contact: Douglas J. Harrison - 713-792-3245
Covenant Children's Hospital
Lubbock, Texas, United States
Status: Recruiting
Contact: Latha Prasannan - 806-725-8000 - jaccresearch@covhs.org
Children's Hospital of San Antonio
San Antonio, Texas, United States
Status: Recruiting
Contact: Timothy C. Griffin - 713-798-1354 - burton@bcm.edu
Methodist Children's Hospital of South Texas
San Antonio, Texas, United States
Status: Recruiting
Contact: Jaime Estrada - 210-575-7000
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Status: Recruiting
Contact: Anne-Marie R. Langevin - 210-450-3800 - CTO@uthscsa.edu
Scott and White Memorial Hospital
Temple, Texas, United States
Status: Recruiting
Contact: Guy H. Grayson - 254-724-5407
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
Status: Recruiting
Contact: Ying J. Hitchcock - 801-581-4477 - clinical.trials@hci.utah.edu
Primary Children's Hospital
Salt Lake City, Utah, United States
Status: Recruiting
Contact: Phillip E. Barnette - 801-585-5270
University of Vermont College of Medicine
Burlington, Vermont, United States
Status: Recruiting
Contact: Alan C. Homans - 802-656-4101
Inova Fairfax Hospital
Falls Church, Virginia, United States
Status: Recruiting
Contact: Marshall A. Schorin - 703-208-6650
Childrens Hospital-King's Daughters
Norfolk, Virginia, United States
Status: Recruiting
Contact: Eric J. Lowe - 757-668-7243
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
Status: Recruiting
Contact: Gita V. Massey - 804-628-1939
Carilion Clinic Children's Hospital
Roanoke, Virginia, United States
Status: Recruiting
Contact: Mandy M. Atkinson - 540-981-7376
Seattle Children's Hospital
Seattle, Washington, United States
Status: Recruiting
Contact: Douglas S. Hawkins - 866-987-2000
Providence Sacred Heart Medical Center and Children's Hospital
Spokane, Washington, United States
Status: Recruiting
Contact: Judy L. Felgenhauer - 800-228-6618 - HopeBeginsHere@providence.org
West Virginia University Healthcare
Morgantown, West Virginia, United States
Status: Recruiting
Contact: Stephan R. Paul - 304-293-2745 - sfilburn@hsc.wvu.edu
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Status: Recruiting
Contact: Kenneth B. DeSantes - 608-262-5223
Marshfield Clinic
Marshfield, Wisconsin, United States
Status: Recruiting
Contact: Michael J. McManus - 715-389-4457
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Status: Recruiting
Contact: John A. Charlson - 414-805-4380
Midwest Children's Cancer Center
Milwaukee, Wisconsin, United States
Status: Recruiting
Contact: Meghen B. Browning - 414-805-4380
Cross Cancer Institute
Edmonton, Alberta, Canada
Status: Recruiting
Contact: Karen E. Mulder - 780-432-8500
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Status: Recruiting
Contact: Caron Strahlendorf - 604-875-2345
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Status: Recruiting
Contact: Shantanu Banerji - 866-561-1026 - CIO_Web@cancercare.mb.ca
Janeway Child Health Centre
Saint John's, Newfoundland and Labrador, Canada
Status: Recruiting
Contact: Lisa Anne B. Goodyear - 866-722-1126
IWK Health Centre
Halifax, Nova Scotia, Canada
Status: Recruiting
Contact: Conrad V. Fernandez - 902-470-8394
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, Canada
Status: Recruiting
Contact: Carol Portwine - 905-521-2100
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada
Status: Recruiting
Contact: Yvan Samson - 514-345-4931
CHUM - Hopital Notre-Dame
Montreal, Quebec, Canada
Status: Recruiting
Contact: Philip Wong - 514-890-8000 - sylvie.beaudoin.chum@ssss.gouv.qc.ca
The Montreal Children's Hospital of the MUHC
Montreal, Quebec, Canada
Status: Recruiting
Contact: Sharon B. Abish - 514-412-4445 - info@thechildren.com
Centre Hospitalier Universitaire de Quebec
Quebec, Canada
Status: Recruiting
Contact: Bruno Michon - 418-525-4444
San Jorge Children's Hospital
San Juan, Puerto Rico
Status: Recruiting
Contact: Luis A. Clavell - 787-765-2363
University Pediatric Hospital
San Juan, Puerto Rico
Status: Recruiting
Contact: Luis A. Clavell - 787-765-2363
Start Date
July 2014
Sponsors
National Cancer Institute (NCI)
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page